Navigation Links
IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
Date:5/15/2008

e program had documented diagnosis of high grade osteosarcoma with relapsed or recurrent disease (locally or metastatic) with resectable or not completely resectable disease, or who are unable to complete recommended chemotherapy due to toxicity.

L-MTP-PE (2 mg/m2 IV over 1 hour) was administered twice a week for 12 weeks followed by once a week for 24 weeks. In addition, some patients in the program were also treated with other agents including aerosol recombinant granulocyte monocyte colony stimulating factor (GM-CSF) an immune stimulating agent (n=20), ifosfamide (n=4), and/or gemcitabine (n=2).

Results to date are as follows:

-- Nine patients are alive with disease.

-- Nine patients have no evidence of disease.

-- Nine patients have died.

-- There are two patients for whom the status is unknown.

Treatment with L-MTP-PE combined with other agents including aerosol GM- CSF was generally well tolerated. Patients treated with chemotherapy had no unexpected toxicities and toxicity from L-MTP-PE infusions was minimal. There were no reports of grade 3 or 4 drug-related toxicities with the exception of fever grade 3 and flu-like symptoms with the first dose. This was prevented with ibuprofen and acetaminophen after subsequent doses. One patient developed pleural and pericardial effusion that was possibly L-MTP-PE and/or GM-CSF related and the patient was removed from the study.

In March, the Company announced that it had formalized a clinical protocol with the FDA, which provides L-MTP-PE to eligible, high-risk osteosarcoma patients through a compassionate access study. The compassionate access study is being conducted initially at M. D. Anderson and Memorial-Sloan Kettering Cancer Center in New York.

"Patients are our first priority and we are committed to providing L-MTP- PE to those who desperately need treatment," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "The potentia
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
3. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
4. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
5. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
8. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
9. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
10. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
11. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Ireland , August 22, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/x34qgv/global_laboratory ) has announced the ... Market 2014-2018"  report to their offering.  ... balance is an essential instrument for any ... the precise weighing of materials. It can ...
(Date:8/22/2014)...  Diplomat, the nation,s largest independent specialty pharmacy, ... in the 2014 Innovations in Specialty Pharmacy Competition, ... of the competition were announced in the August ... Diplomat was honored as a Top Innovator ... Through Diplomat University, the company has implemented a ...
(Date:8/22/2014)... , Aug. 22, 2014 Research ... "Stem Cell Research Products: Opportunities, Tools & Technologies" ... already supply stem cell research products or you wish ... essential and lucrative this market is. The authors know ... sell more effectively to scientists, to generate improved revenues ...
Breaking Medicine Technology:Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher 2Diplomat honored as a Top Innovator by Specialty Pharmacy News 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3
... 2011 Bayer HealthCare Pharmaceuticals Inc. today ... cohort safety study offer insights into the increased risk ... a well-established risk in women who use combination oral ... Specifically, the new data provides healthcare providers with information ...
... Therapeutics today announced  the initiation of a Phase ... XMT-1001 , a novel DNA topoisomerase I inhibitor based ... in second-line gastric cancer and second-/third-line non-small cell lung ... clinical centers in the US.  The Phase 1b follows ...
Cached Medicine Technology:New Interim Data About Combination Oral Contraceptives 2New Interim Data About Combination Oral Contraceptives 3New Interim Data About Combination Oral Contraceptives 4New Interim Data About Combination Oral Contraceptives 5New Interim Data About Combination Oral Contraceptives 6Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer 2Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer 3
(Date:8/22/2014)... Va. (PRWEB) August 22, 2014 On ... Center for Medical and Health Sciences , hosting a ... area’s top influencers in government and public welfare. , ... College of Osteopathic Medicine (LUCOM) joined Liberty staff, ... and the launch of the new medical school. Classes ...
(Date:8/22/2014)... Las Vegas, NV (PRWEB) August 22, 2014 ... authentic content that is written by marketing experts for ... and affiliate links has caught the attention of Shane ... is involved with Internet marketing in any way knows ... or failure in the industry,” reports Michaels. “But even ...
(Date:8/22/2014)... 2014 Japantown Dental is excited to ... whitening technique. Air polishing is a technique used to ... teeth can be caused by a number of factors, ... internal stains. External stains include coffee, wine, tea, smoking ... certain medications, such as tetracycline, and direct trauma to ...
(Date:8/22/2014)... team has found that targeted automated alerts in ... in hospital patients with urinary catheters. In addition, ... the rate of improvement dramatically increased. , The ... urinary catheters in the first place and then ... that have not been removed within a recommended ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 Natural ... Kevin Richardson to restore his own vision from legally blind ... Michaels, prompting an investigative review. , “There is a ... or contacts for everyday function, and most people just think ... to corrective eye surgery that can be pretty risky at ...
Breaking Medicine News(10 mins):Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 3Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 4Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2Health News:Japantown Dental Introduces Air Polishing 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 3Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2
... Inaugural Gala, NORTH ADAMS, Mass., Nov. 14 ... today announced that it will hold,its first Roundtable meeting ... Institute, established by NPSF in May 2007, is a,think ... action for,the field of patient safety. Its goal is ...
... , Ohio -- Scientists are one step closer to ... for supporting life. , For the first time, scientists ... protein molecules to enable different functions to happen. , ... of the Proceedings of the National Academy of Sciences, ...
... your name and initials? Most people do and, as past ... other important behaviors. For example, Jack is more likely to ... is more likely to move to Philadelphia and marry Phyllis. ... it is influential enough to encourage the pursuit of name-resembling ...
... in the World Journal of Gastroenterology on November 7, ... case of gastric carcinosarcoma obtained in this part of ... Tomislav Randjelovic as surgeon and Dr. Branka Filipovic as ... his team; the anatomical and patoanatomical evaluation of macroscopic ...
... Asenapine -- a fast-,dissolving, sublingual tablet being ... and well-tolerated in patients with acute schizophrenia,according to ... of the Journal,of Clinical Psychiatry. These data were ... meeting and at the annual,congress of the European ...
... International,Isotopes Inc. (OTC Bulletin Board: INIS) is pleased ... Chief Financial Officer (CFO),effective November 13, 2007. ... 2007,as Chief Accounting Officer. Ms. McKenzie-Carter has approximately ... Previously, she served as,chief accountant for a sizeable ...
Cached Medicine News:Health News:Lucian Leape Institute Announces First Roundtable 2Health News:Lucian Leape Institute Announces First Roundtable 3Health News:Scientists get first look at how water 'lubricates' proteins 2Health News:What's in a name? Initials linked to success, study shows 2Health News:Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia 2Health News:Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia 3Health News:Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia 4Health News:Laurie McKenzie-Carter Named Chief Financial Officer of International Isotopes Inc. 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: